<DOC>
	<DOCNO>NCT00259155</DOCNO>
	<brief_summary>We recently show majority patient irritable bowel syndrome ( IBS ) abnormal lactulose breath test suggest presence bacterial overgrowth small intestine . In open label double blind treatment IBS subject antibiotic , dramatic improvement clinical symptom observe . In study , antibiotic chosen neomycin , note efficacy 20-25 % normalize lactulose breath test . A efficacious antibiotic need . Therefore aim study determine efficacy rifaximin normalize lactulose breath test IBS subject concomitant improvement clinical symptom .</brief_summary>
	<brief_title>Rifaximin Treatment Irritable Bowel Syndrome</brief_title>
	<detailed_description>1 . Rome I criteria positive IBS subject enrol study inclusion exclusion criterion ( see description inclusion exclusion criterion ) apply . There preference give constipation diarrhea predominant form condition . 2 . Subjects 7-day run phase bowel movement consistency number record ( see Appendix A bowel movement record ) . 3 . At end 7-day run , subject present 12 hour fast lactulose breath test . 4 . Prior breath testing , subject ask fill symptom questionnaire ( Appendix B ) base previous 7 day . Completion questionnaire expect prior start breath test prevent symptom lactulose interfere test . 5 . Subjects provide baseline breath sample 10g lactulose administer . Breath sample obtain every 15 minute 180 minute . The test plot graphically seal technician envelope . The subject investigator blind result test . See detail breath test . 6 . Subjects randomize receive either placebo rifaximin ( 400 mg tid ) 10 day . Compliance test pill count . 7 . On completion treatment , bowel movement consistency number record 7 day . 8 . 7 day completion antibiotic placebo , subject return follow questionnaire ( Appendix C ) breath test . 9 . Subjects send weekly questionnaire period 2 month . During final 7 day 2 month , bowel movement consistency number track . SPECIFIC METHODS : Subject selection enrollment : Subjects select study base Rome I criteria ( 36 ) . This preferred method identify IBS patient avoid pre-selecting patient C- IBS . The goal evaluate methane determinant transit , constipation diarrhea symptom Rome II criterion ( 37 ) . All subject receive prokinetic drug time enrollment need washout period 7 day start study protocol . Subjects identify advertising print medium clinical operation GI motility program Cedars-Sinai Medical Center . Exclusion Criteria : Subjects history inflammatory bowel disease ( 38 ) , diabetes ( 39 ) , previous intestinal surgery ( 40-42 ) , cirrhosis ( 43-47 ) , celiac disease , probiotic use , current proton pump inhibitor use ( 48-54 ) , recent antibiotic use ( past 3 month ) , history bowel obstruction ( 55 ) , narcotic use ( 56 ) age great 65 year ( 57-63 ) exclude . Most condition know influence enteric bacteria level . Women childbearing year undergo pregnancy test participate study ( See detail pregnancy test use ) . Women positive pregnancy test exclude . Lactulose Breath test ( LBT ) : Subjects present GI Motility clinic 12 hour fast . After baseline breath sample ingestion 10g-lactulose syrup ( Inalco Spa , Milano , Italy , package xactdose Inc. , South Beloit , IL ) , end-alveolar breath sample take every 15 minute three hour . Breath sample analyze use model SC Quintron gas chromatograph ( Quintron Instrument Company , Milwaukee , WI ) determine breath hydrogen methane concentration part per million ( ppm ) . Subjects allow smoke exercise within 2 hour prior perform test ( 64 ) . Methane exchange quickly across alveolar membrane , hyperventilation falsely low concentration breath . Subjects also require sit duration breath test exertion increase alveolar clearance gas . If modest hyperventilation occur , concentration carbon dioxide breath sample use correct quality alveolar sampling . Note clinical study breath test result blind investigator patient avoid influence interpretation transit serotonin level . Questionnaires : Three questionnaire use study . The first Stool Form Frequency Questionnaire ( SFFQ ) . This questionnaire design determine consistency stool base standard consistency plot . The second questionnaire design determine duration degree IBS symptom visual analogue score . This questionnaire specifically administer first breath test design determine baseline symptom severity . The final questionnaire follow questionnaire . This questionnaire also plot degree symptom base visual analogue score . However , subject ask rank degree improvement base percent improvement . In last two questionnaire , subject ask consider answer summary precede 7 day . Pregnancy Testing : In human study , pregnancy test perform 1 week prior initiate study . The test specifically perform woman childbearing year . This involve blood draw quantitative determination Beta HCG . The test immunoassay determination total Beta HCG ( Abbott Axsym Test ) perform Cedars-Sinai Clinical Laboratory ( Los Angeles , California ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Subjects select study base Rome I criteria . This preferred method identify IBS patient avoid preselecting patient C IBS . The goal evaluate methane determinant transit , constipation diarrhea symptom Rome II criterion . All subject receive prokinetic drug time enrollment need washout period 7 day start study protocol . Subjects identify advertising print medium clinical operation GI motility program CedarsSinai Medical Center . Subjects history inflammatory bowel disease , diabetes , previous intestinal surgery , cirrhosis , celiac disease , probiotic use , current proton pump inhibitor use , recent antibiotic use ( past 3 month ) , history bowel obstruction , narcotic use age great 65 year exclude . Most condition know influence enteric bacteria level . Women childbearing year undergo pregnancy test participate study ( See detail pregnancy test use ) . Women positive pregnancy test exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Irritable bowel syndrome , Bacterial overgrowth</keyword>
</DOC>